This is a summary of the European public assessment report (EPAR) for Ryzodeg. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ryzodeg.
Therapeutic Indication
Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.
Therapeutic Area (MeSH)
ATC Code
A10AD06
ATC Item
N/A
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| insulin aspart | N/A | insulin aspart |
| insulin degludec | N/A | insulin degludec |
EMA Name
Ryzodeg
Medicine Name
Ryzodeg
Aliases
N/ANo risk management plan link.
